Method for quantifying expression of functionally active topoisomerase II in patients with leukaemia

Journal of Clinical Pathology

Volumn 49, Issue 10, 1996, Pages 848-852

  Cattan, A R ^a   Levett, D ^a   Douglas, E A ^a   Middleton, P G ^a   Taylor, P R A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Drug resistance; Leukaemia; Topoisomerases

Indexed keywords

CHLORAMBUCIL; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ELLIPTICINE; ETOPOSIDE; N ETHYLMALEIMIDE; NOVOBIOCIN; PREDNISOLONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; FLUORESCENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MALE; PRIORITY JOURNAL;

EID: 0029842497     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.49.10.848     Document Type: Article

References (24)

1. Harrison DJ. Molecular mechanisms of drug resistance in tumours. J Pathol 1995;175:7-12.
2. List AF. Preclinical investigations of drug resistance [review]. Curr Opin Oncol 1995;7:19-27.
3. Patel S, Austin CA, Fisher LM. Development and properties of an etoposide-resistant human leukaemic cerfcem cell line. Anti-Cancer Drug Design 1990;5:149-57.
4. Nitiss JL, Liu YX, Hsiung Y. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors. Cancer Res 1993;53:89-93.
5. Erickson LC. The role of O-6-methylguanine DNA methyltransferase (mgmt) in drug resistance and strategies for its inhibition [review]. Semin Cancer Biol 1991;2:257-65.
6. Hall AG, Cattan AR. Drug resistant mechanisms in leukaemia. In: Proctor SJ, ed. Minimal residual disease in leukaemia. London: Bailliere, 1991:655-81.
7. Chen AY, Liu LF. DNA topoisomerases: Essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 1994;34: 101-218.
8. Watt PM, Hickson ID. Structure and function of type II DNA topoisomerases. Biochem J 1994;303:681-05.
9. Drake FH, Zimmerman JP, McCabe FL, Bartus HF, Per SR, Sullivan DM, et al. Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J Biol Chem 1987;262:16739-47.
10. Harker WG, Slade DL, Parr RL, Feldhoff PW, Sullivan DM, Holguin MH. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant hl-60 human leukemia cell line. Cancer Res 1995;55:1707-16.
11. Wells NJ, Hickson ID. Human topoisomerase IIα is phosphorylated in a cell-cycle phase-dependent manner by a proline-directed kinase. Eur J Biochem 1995;231:491-7.
12. Webb CD, Latham MD, Lock RB, Sullivan DM. Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res 1991;51:6543-9.
13. Mestdagh N, Pommery N, Saucier J-M, Hecquet B, Fournier C, Slomianny C, et al. Chemoresistance to doxorubicin and cisplatin in a murine cell line. Analysis of P-glycoprotein, topoisomerase II activity, glutathione and related enzymes. Anticancer Res 1994;14:869-74.
14. Burden DA, Sullivan DM. Phosphorylation of the α and β-isoforms of DNA topoisomerase II is qualitatively different in interphase and mitosis in Chinese hamster ovary cells. Biochemistry 1994;33;14651-5.
15. McKenna SL, West RR, Whittaker JA, Padua RA, Holmes JA. Topoisomerase II α expression in acute myeloid leukaemia and its relationship to clinical outcome. Leukemia 1994;8:1498-502.
16. Doyle LA. Topoisomerase expression in cancer cell lines and clinical samples [review]. Cancer Chemother Pharmacol 1994;34(Suppl):S32-40.
17. Kaufmann SH, Karp JE, Jones RJ, Miller CB, Schneider E, Zwellling LA, et al. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 1994;83: 517-30.
18. Deffie AM, Batra JK, Goldenberg GJ. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res 1989;49:58-62.
19. Ellis AL, Nowak B, Plunkett W, Zwelling LA. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent. Cancer Chemother Pharmacol 1994;34:249-56.
20. Proctor SJ, Taylor P, Thompson RB, Finney R, Reid MM, Hamilton PJ, et al. Acute lymphoblastic leukaemia in adults in the Northern Region of England - a study of 75 cases. Q J Med 1985;57:761-74.
21. Melendy T, Ray DS. Novobiocin affinity purification of a mitochondrial type II topoisomerase from the trypanosomatid Crithidia fasciculata. J Biol Chem 1989;264:1870-6.
22. Davies SM, Robson CN, Davies SL, Hickson ID. Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Chem 1988;263:17724-9.
23. Bradford MM. A rapid and sensitive method for the quantitatiom of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72: 248-54.
24. McKenna SL, Whittaker JA, Padua RA, Holmes JA. Topoisomerase II expression in normal haemopoietic cells and chronic lymphocytic leukaemia: Drug sensitivity or resistance. Leukemia 1993;7:1199-203.